Novo: More type 2 diabetics benefit from early Victoza therapy

09/13/2011 | Reuters

Novo Nordisk said a large number of patients with type 2 diabetes who received early treatment with Victoza met a target level for blood glucose compared with those treated later, according to data presented at a conference of the European Association for the Study of Diabetes. Early use of Victoza also led to greater clinical benefit and improved beta-cell function, the drugmaker reported. Traditionally, metformin is given as first-line therapy for diabetes.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA